🔎 Trials Near Me

Utama › Limfoma Sel Mantel › Kansas

Kajian klinikal Limfoma Sel Mantel di Kansas

7 kajian untuk Limfoma Sel Mantel sedang mencari peserta di lokasi di Kansas.

Bandar di Kansas

Teks kajian rasmi (Bahasa Inggeris)

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • Lawrence Memorial Hospital, Lawrence
  • dan 6 lagi
Mengambil pesertaFasa 3
Umur 60 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05976763

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

  • The University of Kansas Cancer Center, Westwood
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06697184

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • University of Kansas Cancer Center, Kansas City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

DALY II USA/ MB-CART2019.1 for DLBCL

  • University of Kansas Cancer Center, Westwood
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

SynKIR-310 for Relapsed/Refractory B-NHL

  • The University of Kansas Cancer Center, Fairway
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Apr 2026 · NCT06544265

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

  • University of Kansas Hospital, Kansas City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Nov 2025 · NCT05370430

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  • University of Kansas, Westwood
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Nov 2025 · NCT05643742

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.